Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q4 2019 · 10-K
Revenue$100.11M$100.11M+18.6% vs Q4 2018 Net Income-$235.70M-$235.70MN/M vs Q4 2018 EPS Diluted-$3.16-$3.16N/M vs Q4 2018 Operating Income-$230,219,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$181,052,000N/M Margins · derivedOperating margin-230.0%−64.9 pt vs Q4 2018
Net margin-235.4%−68.5 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 26, 2020 · 57 d after period end